Tentarix Biotherapeutics
A San Diego-based start-up developing first-in-class targeted, multifunctional, conditional therapies.
Tentarix is focused on modalities that have cell specific function and has built a team that aims to transform biologics.
In August 2023, the company entered into three, multi-year, collaborations with Gilead Sciences, aiming to leverage its proprietary Tentacles platform to discover and develop multi-functional, conditional protein therapeutics for oncology and inflammatory disease.
Latest Tentarix Biotherapeutics News & Features
23 February 2024
Today's issue
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze